Clinical trial on precise treatment of secretory otitis media according to etiology classification

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2300076404

Enrollment

Unknown

Registered

2023-10-08

Start date

2020-07-01

Completion date

Unknown

Last updated

2023-10-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Secretory otitis media

Interventions

Adenoidal hypertrophy:Drugs are classified by adults

Acute infection:Macrolides of drug, limonene and pinene enteric capsules

Nasosinusitis:Macrolides of drug, limonene and pinene enteric capsules, intranasal corticosteroids

Gastroesophageal reflux:Limonene and pinene enteric capsules, proton pump inhibitors of drug

Rhinitis:Intranasal corticosteroids, limonene and pinene enteric capsules

Allergic rhinitis or Allergic diseases:Antihistamine drug, intranasal corticosteroids, limonene and pinene enteric capsules

Control group:Oral hormones, limonene and pinene enteric capsules

Eligibility

Sex/Gender

All

Age

2 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1.stuffy or conductive deafness or mixed deafness or tinnitus 2.Complete invagination of the tympanic membrane or tympanic effusion 3.tympanogram type B or C2

Exclusion criteria

Exclusion criteria: 1.suppurative otitis media 2.tympanic membrane perforation 3.Patients with tumors 4.severe systemic diseases 5.patients who were lost to follow-up 6.People who are intolerant macrolides or proton pump inhibitors of drug or allergic .

Design outcomes

Primary

Measure	Time frame
Tympanogram;Tympanic membrane examination;	—

Secondary

Measure	Time frame
Inflammatory factor;Detailed medical history;	—

Countries

China

Contacts

Public ContactLiaozhifang

The Second Clinical Medical College

260930229@qq.com+86 137 9856 6543

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026